{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T23:20:51Z","timestamp":1768519251584,"version":"3.49.0"},"posted":{"date-parts":[[2024,12,14]]},"group-title":"Microbiology","reference-count":25,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,12,14]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>BACKGROUND AND OBJECTIVES<\/jats:title>\n                  <jats:p>Apheresis platelets products and plasma are essential for medical interventions, but both still have inherent risks associated with contamination and viral transmission. Platelet products are vulnerable to bacterial contamination due to storage conditions, while plasma requires extensive screening to minimize virus transmission risks. Here we investigate rapid irradiation to sterilizing doses for bacteria and viruses as an innovative pathogen reduction technology.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>MATERIALS AND METHODS<\/jats:title>\n                  <jats:p>\n                    We configured a clinical linear accelerator to deliver ultra-high dose rate (6 kGy\/min) irradiation to platelet and plasma blood components. Platelet aliquots spiked with 10\n                    <jats:sup>5<\/jats:sup>\n                    CFU of\n                    <jats:italic>E.coli<\/jats:italic>\n                    were irradiated with 0.1-20 kGy, followed by\n                    <jats:italic>E.coli<\/jats:italic>\n                    growth and platelet count assays. COVID Convalescent Plasma (CCP) aliquots were irradiated at a virus-sterilizing dose of 25 kGy and subsequently, RBD- specific antibody binding was assessed.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>\n                    1 kGy irradiation of bacteria-spiked platelets reduced\n                    <jats:italic>E.coli<\/jats:italic>\n                    growth by 2.7- log without significant change of platelet count, and 5 kGy or higher produced complete growth suppression. The estimated sterilization (6-log bacterial reduction) dose was 2.3 kGy, corresponding to 31% platelet count reduction. A 25 kGy virus sterilizing dose to CCP produced a 9.2% average drop of RBD-specific IgG binding.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>CONCLUSION<\/jats:title>\n                  <jats:p>This study shows proof-of-concept of a novel rapid blood sterilization technique using a clinical linear accelerator. Promising platelet counts and CCP antibody binding were maintained at bacteria and virus sterilizing doses, respectively. This represents a potential point-of-care blood product sterilization solution. If additional studies corroborate these findings, this may be a practical method for ensuring blood products safety.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>HIGHLIGHTS<\/jats:title>\n                  <jats:list list-type=\"bullet\">\n                    <jats:list-item>\n                      <jats:p>\n                        1 kGy irradiation of bacteria-spiked platelets reduced\n                        <jats:italic>E.coli<\/jats:italic>\n                        growth by 2.7-log without significant change of platelet count, and 5 kGy or higher produced complete growth suppression.\n                      <\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>The estimated sterilization (6-log bacterial reduction) dose was 2.3 kGy, corresponding to 31% platelet count reduction.<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>A 25 kGy virus sterilizing dose to CCP produced a 9.2% average drop of RBD- specific IgG binding.<\/jats:p>\n                    <\/jats:list-item>\n                  <\/jats:list>\n                <\/jats:sec>","DOI":"10.1101\/2024.12.14.628469","type":"posted-content","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T22:20:16Z","timestamp":1734214816000},"source":"Crossref","is-referenced-by-count":0,"title":["Rapid Sterilization of Clinical Apheresis Blood Products using Ultra-High Dose Rate Radiation"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3941-8784","authenticated-orcid":false,"given":"Stavros","family":"Melemenidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khoa D.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosella","family":"Baraceros-Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherie K.","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2768-3082","authenticated-orcid":false,"given":"Joanne","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2715-2779","authenticated-orcid":false,"given":"Hubert","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-7359","authenticated-orcid":false,"given":"M. Ramish","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9681-9210","authenticated-orcid":false,"given":"Rakesh","family":"Manjappa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6613-2984","authenticated-orcid":false,"given":"Suparna","family":"Dutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Armando","family":"Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8331-1626","authenticated-orcid":false,"given":"Nikita","family":"Katila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1195-6596","authenticated-orcid":false,"given":"Brianna","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vignesh","family":"Visvanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy S.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1693-6850","authenticated-orcid":false,"given":"Murat","family":"Surucu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7317-1642","authenticated-orcid":false,"given":"Lawrie B.","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2096-9279","authenticated-orcid":false,"given":"Edgar G.","family":"Engleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2521-0544","authenticated-orcid":false,"suffix":"Jr.","given":"Billy W.","family":"Loo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tho D.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024121702374133000_2024.12.14.628469v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2021.07.008"},{"key":"2024121702374133000_2024.12.14.628469v1.2","doi-asserted-by":"crossref","unstructured":"Bloch EM , Busch MP , Corash LM , Dodd R , Hailu B , Kleinman S , et al. Leveraging Donor Populations to Study the Epidemiology and Pathogenesis of Transfusion- Transmitted and Emerging Infectious Diseases. Transfus Med Rev. 2023;37:150769.","DOI":"10.1016\/j.tmrv.2023.150769"},{"key":"2024121702374133000_2024.12.14.628469v1.3","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1111\/trf.16005","article-title":"Prevalence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in United States blood donations, 2015 to 2019: The Transfusion-Transmissible Infections Monitoring System (TTIMS)","volume":"60","year":"2020","journal-title":"Transfusion"},{"key":"2024121702374133000_2024.12.14.628469v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2020.02.001"},{"key":"2024121702374133000_2024.12.14.628469v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2011.07.007"},{"key":"2024121702374133000_2024.12.14.628469v1.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2006.00697.x"},{"key":"2024121702374133000_2024.12.14.628469v1.7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1997.37497265344.x"},{"key":"2024121702374133000_2024.12.14.628469v1.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2000.tb00065.x"},{"key":"2024121702374133000_2024.12.14.628469v1.9","doi-asserted-by":"publisher","DOI":"10.1191\/096032701718120319"},{"key":"2024121702374133000_2024.12.14.628469v1.10","unstructured":"Investigational COVID-19 Convalescent Plasma; Guidance for Industry."},{"key":"2024121702374133000_2024.12.14.628469v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.09.018"},{"key":"2024121702374133000_2024.12.14.628469v1.12","doi-asserted-by":"crossref","unstructured":"Wang J , Melemenidis S , Manjappa R , Viswanathan V , Ashraf RM , Levy K , et al. Dosimetric calibration of an anatomically specific ultra-high dose rate electron irradiation platform for preclinical FLASH radiobiology experiments. 2023.","DOI":"10.1002\/mp.17432"},{"key":"2024121702374133000_2024.12.14.628469v1.13","unstructured":"Ashraf MR , Melemenidis S , Liu K , Grilj V , Jansen J , Velasquez B , et al. Multi- Institutional Audit of FLASH and Conventional Dosimetry with a 3D-Printed Anatomically Realistic Mouse Phantom. Int J Radiat Oncol Biol Phys. 2024;:S0360- 3016(24)00433-4."},{"key":"2024121702374133000_2024.12.14.628469v1.14","first-page":"17","article-title":"Standards for blood banks and transfusion services","volume":"3","year":"1977","journal-title":"QRB Qual Rev Bull"},{"key":"2024121702374133000_2024.12.14.628469v1.15","unstructured":"Pathogen-reduced platelets. Professional Education. 2022. Cited 2024 Jun 16. Available from https:\/\/professionaleducation.blood.ca\/en\/transfusion\/clinical-guide\/pathogen-reduced-platelets."},{"key":"2024121702374133000_2024.12.14.628469v1.16","doi-asserted-by":"crossref","unstructured":"R\u00f6ltgen K , Powell AE , Wirz OF , Stevens BA , Hogan CA , Najeeb J , et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5:eabe0240.","DOI":"10.1126\/sciimmunol.abe0240"},{"key":"2024121702374133000_2024.12.14.628469v1.17","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2021-0215-SA"},{"key":"2024121702374133000_2024.12.14.628469v1.18","unstructured":"Recommendations for Investigational and Licensed COVID-19 Convalescent Plasma; Guidance for Industry."},{"key":"2024121702374133000_2024.12.14.628469v1.19","doi-asserted-by":"publisher","DOI":"10.1139\/m90-126"},{"key":"2024121702374133000_2024.12.14.628469v1.20","doi-asserted-by":"crossref","unstructured":"Hume AJ , Ames J , Rennick LJ , Duprex WP , Marzi A , Tonkiss J , et al. Inactivation of RNA Viruses by Gamma Irradiation: A Study on Mitigating Factors. Viruses. 2016;8:204.","DOI":"10.3390\/v8070204"},{"key":"2024121702374133000_2024.12.14.628469v1.21","doi-asserted-by":"publisher","DOI":"10.1128\/am.22.1.61-65.1971"},{"key":"2024121702374133000_2024.12.14.628469v1.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1989.tb02033.x"},{"key":"2024121702374133000_2024.12.14.628469v1.23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1537-2995.1991.31191096182.x","article-title":"Inactivation of human immunodeficiency virus by gamma radiation and its effect on plasma and coagulation factors","volume":"31","year":"1991","journal-title":"Transfusion"},{"key":"2024121702374133000_2024.12.14.628469v1.24","doi-asserted-by":"publisher","DOI":"10.1006\/biol.2002.0330"},{"key":"2024121702374133000_2024.12.14.628469v1.25","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.18-0937"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.12.14.628469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:40:40Z","timestamp":1768462840000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.12.14.628469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,14]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1101\/2024.12.14.628469","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.3390\/ijms26062424","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,12,14]]},"subtype":"preprint"}}